| |
| | |
Neutralizing Antivector Antibodies | | |  |
BioReliance Launches Next-Generation Genotoxicity Screening Service
BioReliance has contracted with Gentronix to offer their GreenScreen HC in vitro assay as a major part of BioReliance's portfolio of genotoxicity screening services. GreenScreen HC, in conjunction with Ames II assays, allows pharmaceutical companies to test for genotoxic potential earlier in the preclinical development process, using only a few milligrams of test compound as opposed to the gram quantities required by current ICH regulatory tests. Click here to read the press release.
Bioreliance Launches iNet, a Web-Based Tool for tracking Electronic Submissions of Biologics Tests
BioReliance is pleased to announce the release of iNet, a proprietary information technology system for submitting and tracking test article details via a controlled and secure Internet access from any location worldwide. Now you can view the status of current and past studies, keep informed of when testing will be completed, download reports, and allow your colleagues to view the status of your tests. iNet is currently available to US biologics testing customers upon request, but will be made available to a larger audience soon. Click here to read the press release.
|
|
|
|
|
BioReliance has significant experience in producing and testing gene therapy viral vectors.
|
Antivector antibodies are detected by using specific ELISA assays. Antivector immunoglobulin (IgG) in human serum samples is detected by using ELISA plates coated with virus. Bound antivector IgG is detected by using antihuman IgG antibody conjugated to an enzyme. Neutralizing antibodies are detected by using a format similar to the infectivity assays, except that both virus and serial dilutions of human serum are inoculated onto the detector cells. Results are expressed as serum titer giving 50% neutralization of infectivity.
|  |
|
|
